Novel Therapeutic Approaches in the Treatment of Multiple Myeloma

Last Modified: April 14, 2004

Share article


Conference Dates: Friday, May 21, 2004
Conference Location: Double Tree Hotel, Philadelphia, PA


Sponsoring Group: Multiple Myeloma Research Foundation & UPENN School of Medicine

Conference Web Page URL: www.multiplemyeloma.org/events

Topics Covered: Upon completion of this program, the participants should be able to:

  1. Identify the prognostic indicators and diagnostic approaches to multiple myeloma
  2. Discuss the latest advances in stem cell transplantation, treatments for bone disease, and supportive care management.
  3. Describe the role and appropriate use of novel treatments for multiple myeloma throughout the disease progression.

Conference Objectives: This course will provide a comprehensive overview of the latest information on multiple myeloma biological and clinical research.

Who Should Attend: Medical Oncologists, Hematologists, Oncology Nurses, Internists with recently diagnosed patients

Conference Agenda:

  • 8:00 AM
    Breakfast and Registration
  • 8:30 AM
    Welcome & Introduction
    Edward Stadtmauer, MD
  • 8:45 AM
    MM Disease Overview: Prognostic Indicators & Staging
    Philip Greipp, MD
  • 9:15 AM
    Advances in Bone Disease Therapy & Supportive Care Management
    Harold Harvey, MD (invited)
  • 9:45 AM
    Advances in Initial Therapies for Treating Multiple Myeloma
    S. Vincent Rajkumar, MD
  • 10:15 AM
    BREAK
  • 10:30 AM
    The Role of Transplantation in Multiple Myeloma
    Edward Stadtmauer, MD
  • 11:00 AM
    Novel Therapies and Clinical Trials in Multiple Myeloma: New Paradigm For Relapsed or Refractory Patients
    Michael Schuster, MD
  • 11:30 AM
    Question & Answer  Faculty Panel
  • 12:00 PM
    Evaluation and Adjourn

Registration Information: Contact: Sara Nichols, (tel) 203.652.0206, (fax) 203.972.1259, (email) nicholss@themmrf.org

Conference Fees: $20

Continuing Education: Yes


News
ASH: Novel Drug Beneficial in Multiple Myeloma

Oct 21, 2014 - In patients with relapsed or resistant multiple myeloma who have received up to three prior therapies excluding the first-generation proteasome inhibitor bortezomib, treatment with the second-generation proteasome inhibitor carfilzomib is associated a high response rate and a low incidence of side effects, according to research presented at the annual meeting of the American Society of Hematology, held from Dec. 5 to 8 in New Orleans.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More